

Public Health and Primary Health Care  
Communicable Disease Control  
4th Floor, 300 Carlton St, Winnipeg, MB R3B 3M9  
T 204 788-6737 F 204 948-2040  
[www.manitoba.ca](http://www.manitoba.ca)

January 31, 2012

Dear Colleague:

**Re: Management of Gonococcal Infections and Treatment Kits**

**Clarification of PHAC Notice for Management of Gonococcal Infection**

- As clarification to several questions on the interpretation of the guidelines and as a follow up to the MH letter dated Dec 21, 2011, please note:
  1. Increased cephalosporin dose (i.e. Cefixime PO 800 mg x 1; or Ceftriaxone 250 mg i.m. x1) is recommended for treatment of ALL cases and contacts
  2. Culture and sensitivity testing, is recommended for all symptomatic MSM and in other special situations as outlined in the notice - to enhance surveillance for resistant patterns.

PHAC Notice available at: <http://www.phac-aspc.gc.ca/std-mts/sti-its/alert/2011/alert-gono-eng.php>

**Unused STI Medication (Cefixime 400 mg kits)**

- Taché Pharmacy will be providing all clinics which have received the Cefixime 400 mg kits in the last 6 months with instructions shortly on how to use them in regards to the new updated guidelines.

**Updated STI Medication Order Form and STI Medication Administration Form**

- Please note the administration form is to be completed for every treatment administered.
- These forms can be found at: <http://www.gov.mb.ca/health/publichealth/cdc/sti/cgsl.html>

Please share this information with all relevant Colleagues in your facility or clinic.

Sincerely,

*“Original Signed By”*

Kathleen Messner R.N. B.N.  
A/ Director, Communicable Disease Control